June 6, 2010

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Transplant recipients who are CMV-negative and receive a kidney from a CMV-positive donor are at increased risk for CMV infection post-transplant. In this double-blind randomized controlled trial, prophylaxis with valganciclovir for 200 days reduced the incidence of CMV infection in the first year post-transplant, as compared to 100 days of prophylaxis.



Renal Transplantation